MedTech Venture Builder Collaborative Centre of Excellence

Starting July 2025 - Accepting Expressions of Interest

The MedTech Venture Builder (MVB), now in its 2nd year, is a 12-month structured programme in two stages to speed-up the commercial translation of promising medical technologies into robust, investment-ready healthcare ventures.

Supporting companies from across the UK, the MVB, the first of its kind, is a collaborative effort between London’s leading academic institutions, King’s College London (lead), Queen Mary University London, and City & St. George's University London.

King's College London, Queen Mary University of London, City, University of London, St George's University of London logos

Our collaborative focus on MedTech allows us to take ventures a significant step further than what has been achieved before programmatically.

We provide the structures that are critical to de-risking your company, such as a regulatory plan, a clinical evidence roadmap and stakeholder mapping, extensive hands-on guidance and monthly strategic progress review, all within a fit-for-purpose Quality Management System (QMS).

This is a truly unique opportunity for very select, high-potential MedTech companies from across the UK to receive fully customised, extensive executive support from experts in commercial translation from the partner institutions.

This is only possible with the support of a significant grant by Research England for a Collaborative Centre of Excellence (CCoE) for MedTech translation. The programme is further supported by our strategic partners, Cambridge Consultants.

Research England logo and Cambridge Consultants logo

What we offer

Space at the London Institute for Healthcare Engineering for up to 3 team members per venture, part-time, for the duration of the programme.

Stage 1 (6-month duration): Foundation

Hands-on strategic milestone development
Validation of your business case
Familiarisation with the rigorous processes, tools and methods of an established MedTech company with industry experts

Stage 2 (6-month duration): Execution

Deep investment readiness training - beyond pitching
Development of a regulatory plan with hands-on expert support
Access to an ISO13485 Quality Management System, with hands-on support to develop a technical file towards regulatory submission
Health technology assessment to generate a robust value proposition for the venture’s offering, with identified stakeholders
Generation of a clinical protocol for clinical studies/trials (where applicable and deemed feasible by the Venture Builder experts)
Ongoing community support post-programme

Key outcomes

By participating in the MedTech Venture Builder your venture will:

Have moved to its next value inflection point in commercial terms
Have validated and strengthened its technology's commercial viability
Have systematically advanced towards being a compliant, investment-ready healthcare venture
Have developed core skills in following rigorous MedTech processes
Have completed a regulatory plan and critical documentation under a Quality Management System
Have de-risked your proposition for investment, making you investment-worthy
Have expanded contacts with industry partners and investors

Eligibility

The MedTech Venture Builder invites applications from:

UK-based registered companies commercialising a medical device as defined under the UK (Directive 93/42/EEC on medical devices) and EU (Medical Devices Regulation (EU) 2017/745) regulatory framework(s). In-Vitro Diagnostics are not eligible
Institutional or non-institutional intellectual property acceptable
Agnostic on funding stage, but with enough runway to complete the programme
Companies with innovations in the following focus areas are explicitly invited to apply: Cancer; regulated Women's Health; Surgery
Sofware as a Medical Device (SaMD) companies are strongly recommended to apply

Minimum requirements to apply

For registered companies only
Technologies should be at minimum proof of concept stage (TRL 4) with initial evidence
Cross-functional leadership team in place with complementary skills, clinical lead as part of the team is advisable
Shareholding agreed between founders, including with any founding academic institution
Commitment expected: Min of 1 day a week for Stage 1, 2 days a week for Stage 2

Important information

There are costs associated with joining this programme. These will be communicated in advance of opening for applications
All sessions and support offered are in person in London